Inspire(US:INSP) Globenewswire·2025-12-24 02:14Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota and claims that Inspire Medical and its executives concealed critical operational issues that hindered the successful launch of the Inspire V device [1][3]. - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are eligible to participate in the lawsuit [2]. Group 2: Allegations of Concealment - The lawsuit alleges that Inspire Medical misrepresented its "operational readiness" for the Inspire V launch, claiming it was prepared for a full commercial rollout, while in reality, significant operational failures existed [3][4]. - Key undisclosed operational issues include: - Medicare claims processing software updates were not effective until July 1, 2025, delaying the rollout and revenue generation [4]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V, leading to an 80% cut in 2025 EPS guidance [4]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a $42.04 per share drop and a 32.4% decline in stock value [4]. Group 3: Investigation Focus - Hagens Berman's investigation emphasizes the concealment of the Medicare claims software failure and the inventory glut of the prior Inspire IV device as critical points leading to the stock collapse [5]. - The firm asserts that management prioritized a narrative of a seamless transition over the actual operational challenges faced [5].